Lynch syndrome carriers have about a twofold increased risk of prostate cancer (PCa), data suggest.
To quantify prostate cancer risk in Lynch syndrome, Victoria M. Raymond, from the University of Michigan in Ann Arbor, and colleagues reviewed the cancer histories of probands and their relatives (first- through fourth-degree) for 198 independent mutation-positive Lynch syndrome families, which included 4,127 men.
The researchers identified 97 PCa cases. PCa was diagnosed at a median age of 65 years, with 11.5% of cases diagnosed before the age of 50 years. At age 60 years, the cumulative risk of prostate cancer was 6.3% compared with a population risk of 2.6%, the researchers reported online ahead of print in the Journal of Clinical Oncology. The corresponding risks at age 80 years were 30% and 17.8%, respectively.
“Our finding that Lynch syndrome is associated with an increased risk of prostate cancer is clinically valuable for patients and clinicians when weighing risks and benefits of screening, and we suggest that prostate cancer screening be offered to this high-risk group,” the authors wrote.